title: Glutamine-supplemented tube feedings versus total parenteral nutrition in children receiving intensive chemotherapy.
abstract: Although enteral nutrition is generally advocated in the care of children with cancer, those patients receiving intensive chemotherapy alone or in combination with bone marrow transplantation often require total parenteral nutrition (TPN). Two patients are presented illustrating some differences between enteral and parenteral feedings in children receiving intensive chemotherapy. Nasogastric glutamine-supplemented tube feedings were well tolerated both in the hospital and at home. The cost of care for the enterally supported child was less than one third of the TPN-supported child. Although TPN appears to be beneficial in some patients with cancer, it is expensive and is associated with several significant disadvantages. Among these are an increased incidence of both gram-positive and gram-negative infections and an increased incidence of gastrointestinal symptoms. Enteral nutrition is less costly than TPN and maintains the structural and functional integrity of the intestinal mucosa. The addition of certain substrates such as glutamine, arginine and omega-3 fatty acids may improve the body's immune response as well. We hypothesize that early glutamine supplemented tube feedings in children receiving intensive chemotherapy alone or in combination with bone marrow transplantation will result in improved nutrition with fewer infections and lower cost than TPN-supplemented patients. In addition, a shorter hospital stay and improved quality of life are anticipated.
authors.affiliation: Department of Pediatric Hematology/Oncology, Vanderbilt Children's Hospital, Nashville, TN, USA.
authors.forename: C
authors.initials: C
authors.lastname: Ford
authors.forename: J A
authors.initials: JA
authors.lastname: Whitlock
authors.forename: J B
authors.initials: JB
authors.lastname: Pietsch
mesh_terms: D016026:Bone Marrow Transplantation; D004750:Enteral Nutrition / Q000191:economics; D005240:Feasibility Studies; D005260:Female; D005503:Food Additives / Q000627:therapeutic use; D005973:Glutamine / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009930:Organic Chemicals; D010289:Parenteral Nutrition, Total / Q000009:adverse effects / Q000191:economics
chemical_list: D005503:Food Additives; D009930:Organic Chemicals; D005973:Glutamine; C011567:Vivonex